GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Genomma Lab Internacional SAB de CV (MEX:LABB) » Definitions » Return-on-Tangible-Equity

Genomma Lab InternacionalB de CV (MEX:LABB) Return-on-Tangible-Equity : 39.09% (As of Mar. 2025)


View and export this data going back to 2008. Start your Free Trial

What is Genomma Lab InternacionalB de CV Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Genomma Lab InternacionalB de CV's annualized net income for the quarter that ended in Mar. 2025 was MXN1,995 Mil. Genomma Lab InternacionalB de CV's average shareholder tangible equity for the quarter that ended in Mar. 2025 was MXN5,103 Mil. Therefore, Genomma Lab InternacionalB de CV's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2025 was 39.09%.

The historical rank and industry rank for Genomma Lab InternacionalB de CV's Return-on-Tangible-Equity or its related term are showing as below:

MEX:LABB' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -99.95   Med: 31.02   Max: 83.32
Current: 44.32

During the past 13 years, Genomma Lab InternacionalB de CV's highest Return-on-Tangible-Equity was 83.32%. The lowest was -99.95%. And the median was 31.02%.

MEX:LABB's Return-on-Tangible-Equity is ranked better than
91.03% of 903 companies
in the Drug Manufacturers industry
Industry Median: 6.67 vs MEX:LABB: 44.32

Genomma Lab InternacionalB de CV Return-on-Tangible-Equity Historical Data

The historical data trend for Genomma Lab InternacionalB de CV's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genomma Lab InternacionalB de CV Return-on-Tangible-Equity Chart

Genomma Lab InternacionalB de CV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 44.77 29.60 28.28 22.16 32.44

Genomma Lab InternacionalB de CV Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.00 50.29 49.58 37.32 39.09

Competitive Comparison of Genomma Lab InternacionalB de CV's Return-on-Tangible-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genomma Lab InternacionalB de CV's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Genomma Lab InternacionalB de CV's Return-on-Tangible-Equity falls into.


;
;

Genomma Lab InternacionalB de CV Return-on-Tangible-Equity Calculation

Genomma Lab InternacionalB de CV's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=1493.122/( (4338.408+4867.503 )/ 2 )
=1493.122/4602.9555
=32.44 %

Genomma Lab InternacionalB de CV's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=1994.876/( (4867.503+5338.757)/ 2 )
=1994.876/5103.13
=39.09 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2025) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Genomma Lab InternacionalB de CV  (MEX:LABB) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Genomma Lab InternacionalB de CV Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Genomma Lab InternacionalB de CV's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Genomma Lab InternacionalB de CV Business Description

Traded in Other Exchanges
Address
Avenida Antonio Dovali Jaime, Number 70, Tower C, Floor 2, Office A. Colonia Santa Fe, Del. Alvaro Obregon, Mexico, MEX, MEX, CP 01210
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Genomma Lab InternacionalB de CV Headlines

No Headlines